Physician profile
David W Griffiths
NPI 1366406076
$6,430.38
in general payments reported to CMS, 2019-2025
47 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $808 · 2021: $1,249 · 2022: $1,149 · 2023: $835 · 2024: $437 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $858.38 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $480.77 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $447.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.34 | 2019-2023 | Breztri |
| Amarin Pharma, INC. | $359.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.38 | 2019-2023 | Trulance, Xifaxan |
| Amgen INC. | $323.21 | 2019-2024 | Otezla, Repatha, Prolia |
| Daiichi Sankyo INC. | $314.88 | 2020-2022 | |
| Abbvie INC. | $313.30 | 2021-2025 | |
| Mylan Specialty L.P. | $297.27 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.85 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $243.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $186.65 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil |
| Novartis Pharmaceuticals Corporation | $163.41 | 2019-2024 | |
| Lilly USA, LLC | $160.55 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Griffiths listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.